Mind Medicine (MindMed) Future Growth
Future criteria checks 0/6
Mind Medicine (MindMed) is forecast to grow earnings and revenue by 52% and 62.6% per annum respectively. EPS is expected to grow by 50.7% per annum. Return on equity is forecast to be -43.7% in 3 years.
Key information
52.0%
Earnings growth rate
50.69%
EPS growth rate
| Pharmaceuticals earnings growth | 12.9% |
| Revenue growth rate | 62.6% |
| Future return on equity | -43.68% |
| Analyst coverage | Good |
| Last updated | 05 Jan 2026 |
Recent future growth updates
Recent updates
MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy
Oct 14Mind Medicine: Initiating Hold Rating Due To Regulatory Challenges
Apr 21MindMed's LSD Anxiety Drug: Revisiting, Rethinking, But Maintaining My 'Hold' Call
Jan 29Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate
Nov 04Psychedelic Stocks: Focus On Their Cash
Aug 15MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors
Jun 05Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data
Apr 04Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts
Feb 02Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans
May 23
We're Hopeful That Mind Medicine (MindMed) (NASDAQ:MNMD) Will Use Its Cash Wisely
Feb 07MindMed: Not The Horse To Back If You're Looking To Buy Psychedelics
Oct 19MindMed announces proposed public offering of common shares
Sep 27MindMed doses first patient in phase 1 trial examining psychedelic MDMA-like substances
Sep 20Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 204 | -14 | -82 | 104 | 10 |
| 12/31/2027 | 36 | -171 | -170 | -115 | 10 |
| 12/31/2026 | N/A | -192 | -179 | -175 | 11 |
| 12/31/2025 | N/A | -180 | -128 | -133 | 11 |
| 9/30/2025 | N/A | -168 | -114 | -114 | N/A |
| 6/30/2025 | N/A | -115 | -102 | -102 | N/A |
| 3/31/2025 | N/A | -78 | -92 | -92 | N/A |
| 12/31/2024 | N/A | -109 | -79 | -79 | N/A |
| 9/30/2024 | N/A | -98 | -74 | -74 | N/A |
| 6/30/2024 | N/A | -102 | -74 | -74 | N/A |
| 3/31/2024 | N/A | -125 | -68 | -68 | N/A |
| 12/31/2023 | N/A | -96 | -64 | -64 | N/A |
| 9/30/2023 | N/A | -77 | -57 | -57 | N/A |
| 6/30/2023 | N/A | -75 | -49 | -49 | N/A |
| 3/31/2023 | N/A | -63 | -51 | -51 | N/A |
| 12/31/2022 | N/A | -57 | -50 | -50 | N/A |
| 9/30/2022 | N/A | -69 | -45 | -45 | N/A |
| 6/30/2022 | N/A | -69 | -53 | -53 | N/A |
| 3/31/2022 | N/A | -98 | -49 | -49 | N/A |
| 12/31/2021 | N/A | -93 | -46 | -46 | N/A |
| 9/30/2021 | N/A | -89 | -45 | -45 | N/A |
| 6/30/2021 | N/A | -80 | -34 | -34 | N/A |
| 3/31/2021 | N/A | -41 | -29 | -29 | N/A |
| 12/31/2020 | N/A | -34 | -24 | -24 | N/A |
| 9/30/2020 | N/A | -29 | -22 | -22 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MNMD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MNMD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MNMD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MNMD is forecast to have no revenue next year.
High Growth Revenue: MNMD is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MNMD is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/08 06:55 |
| End of Day Share Price | 2026/01/08 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mind Medicine (MindMed) Inc. is covered by 21 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Christopher Chen | Baird |
| null null | Baird |